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Acetylcysteine Reduces Plasma Homocysteine Concentration
and Improves Pulse Pressure and Endothelial Function in
Patients With End-Stage Renal Failure
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Walter Zidek, MD; Martin Tepel, MD
Background—Increased oxidative stress, elevated plasma homocysteine concentration, increased pulse pressure, and
impaired endothelial function constitute risk factors for increased mortality in patients with end-stage renal failure.
Methods and Results—We investigated the metabolic and hemodynamic effects of intravenous administration of
acetylcysteine, a thiol-containing antioxidant, during a hemodialysis session in a prospective, randomized, placebo-
controlled crossover study in 20 patients with end-stage renal failure. Under control conditions, a hemodialysis session
reduced plasma homocysteine concentration to 5822% predialysis (meanSD), whereas in the presence of
acetylcysteine, the plasma homocysteine concentration was significantly more reduced to 127% predialysis (P0.01).
The reduction of plasma homocysteine concentration was significantly correlated with a reduction of pulse pressure. A
10% decrease in plasma homocysteine concentration was associated with a decrease of pulse pressure by 2.5 mm Hg.
Analysis of the second derivative of photoplethysmogram waveform showed changes of arterial wave reflectance during
hemodialysis in the presence of acetylcysteine, indicating improved endothelial function.
Conclusions—Acetylcysteine-dependent increase of homocysteine removal during a hemodialysis session improves
plasma homocysteine concentration, pulse pressure, and endothelial function in patients with end-stage renal failure.
(Circulation. 2004;109:369-374.)
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Patients with end-stage renal failure show increased car-diovascular mortality attributable to accumulation of
several risk factors, including hypertension, anemia, oxida-
tive stress, and elevated plasma homocysteine concentration.
A significant increase of plasma homocysteine levels in
patients with end-stage renal failure has been shown by
several groups and correlated with arteriosclerotic vascular
diseases and mortality.1–5
See p 294
A recent analysis showed that an increase of plasma
homocysteine concentration is associated with increased
blood pressure.6 Increased plasma homocysteine concentra-
tion is associated with increased oxidative stress, which is in
part responsible for the endothelial dysfunction observed in
patients with end-stage renal failure.7 Impaired endothelial
function is associated with abnormalities of arterial wave
reflectance, contributing to increased pulse pressure. Pulse
pressure itself is known to be an important independent
predictor of cardiovascular mortality in patients with end-
stage renal failure.8 Therefore, hyperhomocysteinemia, in-
creased oxidative stress, endothelial dysfunction, abnormali-
ties in arterial wave reflectance, and increased pulse pressure
all contribute to the increased cardiovascular morbidity in
patients with end-stage renal failure.
Several attempts have been made to reduce elevated
plasma homocysteine concentration. In the general popula-
tion, supplementation with folic acid and vitamin B12 re-
duces plasma homocysteine concentration by approximately
one quarter to one third.9 In patients with end-stage renal
failure, the administration of folic acid or folinic acid de-
creased total homocysteine concentration between 32% and
46%.10,11
Our group recently showed that acetylcysteine, a thiol-
containing antioxidant, is able to significantly reduce com-
posite cardiovascular end points in patients with end-stage
renal failure.12 Intravenous administration of acetylcysteine in
healthy subjects significantly reduced plasma homocysteine
concentration.13 Because during a standard hemodialysis
session, plasma homocysteine concentration decreases by
only approximately 28%, we reasoned that the administration
of acetylcysteine during a hemodialysis session can drasti-
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cally improve elevated plasma homocysteine concentration in
patients with end-stage renal failure.14 Usually, patients with
end-stage renal failure already receive extensive oral medi-
cation. We therefore reasoned that the intravenous adminis-
tration of acetylcysteine during hemodialysis is superior
compared with oral administration because of better patient
compliance.
We investigated the effects of intravenous administration
of acetylcysteine during a single hemodialysis session on
plasma homocysteine concentration in a prospective, random-
ized, placebo-controlled crossover design. Our results
showed that the administration of acetylcysteine was able to
completely normalize plasma homocysteine concentration in
hemodialysis patients and was significantly associated with a
reduction of pulse pressure and an improvement in endothe-
lial function, both indicating an improvement of vascular
function.
Methods
Patients
Twenty patients with end-stage renal failure were enrolled in this
study. None of the patients received any supplementation with folic
acid, folinic acid, vitamin B6, or vitamin B12. All of the patients
were routinely dialyzed for 4 hours 3 times weekly using a
biocompatible polysulfone membrane (F8, Fresenius Medical Care)
with no dialyzer reuse. The dialysis solutions used were bicarbonate-
based. Kt/V values (the amount of plasma cleared of urea divided by
the urea distribution volume) was measured according to Daugirdas’
formula.15 In a crossover design, each patient received acetylcysteine
(5 g in 5% glucose solution for 4 hours) during a single hemodialysis
session and 5% glucose solution alone for placebo control during
another hemodialysis session. Acetylcysteine or glucose for placebo
control was given on 2 consecutive regular hemodialysis sessions.
Patients were randomly assigned to the order of administration of
acetylcysteine or placebo. The dosage of acetylcysteine is in the
range that has been reported to efficiently reduce plasma homocys-
teine concentration in healthy subjects.13 In addition, a dosage of 150
mg/kg acetylcysteine has been given intravenously to prevent
contrast-induced nephropathy.16 No serial administration of acetyl-
cysteine was intended in this study. The local ethics committee
approved the study protocol, and all patients gave written informed
consent.
Biochemical Measurements
Samples of venous blood were drawn from the arterial-venous fistula
immediately before and at the end of the hemodialysis session.
Plasma was separated from blood cells by immediate centrifugation.
Plasma homocysteine concentration was measured by high-perfor-
mance liquid chromatography method with fluorescence
detection.17,18
Fingertip Photoplethysmography
Analysis of the second derivative of photoplethysmogram waveform
was used to characterize pulse waves during the hemodialysis
session. In contrast to other hemodynamic methods, the use of
fingertip photoplethysmography is advantageous, because pulse
waves can be continuously measured during the hemodialysis
without affecting the dialysis procedure or the patient. Photoplethys-
mography was conducted using a Vitaguard VG3000 monitor
(Getemed) with the sensor located at the cuticle of the third digit of
the hand contralateral to the location of vascular hemodialysis
access. Raw data were collected at a rate of 32 per second,
transferred to a personal computer, and additionally analyzed with
self-made software. For each measurement point, data from 10 beats
were averaged and differentiated 2 times (GraphPad prism 3.0,
Graph Pad Software). The second derivative of photoplethysmogram
waveform consisted of several separate peaks, as shown in Figure 1.
The ratios of the first peak (a) and the second peak (b, creating the
ab ratio) or the forth peak (d, creating the ad ratio) were calculated.
The absolute values were used for the calculations. The initial ab
ratios or ad ratios measured before the start of the hemodialysis
session were set to 100% (control values).
To show the characteristics of endothelium-dependent flow-
mediated vasodilation by fingertip photoplethysmography, healthy
control subjects were studied during reactive hyperemia, an estab-
lished method to investigate endothelial function.19 Pulse waves
obtained on the ipsilateral arm during reactive hyperemia evoked by
the release of a cuff on the upper arm were analyzed. The sphyg-
momanometric cuff was placed above the antecubital fossa. The cuff
was inflated to 240 mm Hg for 5 minutes to evoke transient ischemia
and consequent dilation of downstream resistance vessels via auto-
regulatory mechanisms. Subsequent cuff deflation induces a brief
high-flow state, increases shear stress, and increases endothelium-
dependent nitric oxide production and hence endothelium-dependent
vasodilation. Fingertip photoplethysmography was conducted in 7
healthy control subjects, who did not take any medication and were
free of intercurrent illness, and ab ratios and ad ratios were derived
from analysis of second derivative of photoplethysmogram wave-
form. Healthy control subjects did not receive acetylcysteine. To
assess endothelium-independent vasodilation, 0.4 mg of nitroglycer-
in was administered sublingually.
Statistics
Data are given as meanSD if not indicated otherwise. An estimate
of the sample size had been made beforehand (GraphPad Instat,
GraphPad Software). To determine the sample size, a standard
deviation of 8 mol/L for plasma homocysteine was expected in
patients with end-stage renal failure. Assuming a mean difference of
9 mol/L, at least 17 patients were needed to obtain a 90% power of
the study. Differences between groups were analyzed using Wilcox-
on Mann-Whitney test (GraphPad prism 3.0). Multivariate regression
analysis was conducted using SPSS for windows, version 11.5.
Two-sided P values below 0.05 were considered to indicate statis-
tical significance.
Results
The clinical and biochemical characteristics of 20 patients
with end-stage renal failure are shown in Table 1. Hemodi-
alysis was performed in the absence (placebo control) and
presence of acetylcysteine in a prospective, randomized,
Figure 1. Representative photoplethysmogram waveform (top)
and its second derivative of waveform (f, bottom) obtained from
a healthy control subject. For each measurement point, data
from 10 beats were averaged and presented as meanSEM.
The peaks of the second derivative of photoplethysmogram
waveform are labeled as follows: a, first peak; b, second peak;
c, third peak; and d, fourth peak.
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crossover design. Under control conditions and in the pres-
ence of acetylcysteine, hemodialysis sessions were performed
after an essentially equal procedure. In both groups (placebo
control versus acetylcysteine), there were similar Kt/V values
(placebo, 1.10.3; acetylcysteine, 1.20.2; P0.38), ultra-
filtration volumes (placebo, 2.21.2 L; acetylcysteine,
2.51.1 L; P0.50), hematocrit (placebo, 1029% predialy-
sis; acetylcysteine, 10513% predialysis; P0.32), and se-
rum protein concentrations (placebo, 10410% predialysis;
acetylcysteine, 10717% predialysis; P0.62).
The intravenous administration of acetylcysteine during
the hemodialysis session did not show any clinical side
effects in the 20 patients studied. This is in accordance with
the results of a previous study by our group, where acetyl-
cysteine was administered orally for a median of 14.5 months
in patients with end-stage renal failure.18 In that study, 5
patients (8%) reported gastrointestinal discomfort during
treatment with acetylcysteine, and no major side effects were
observed. Hypotension may be a side effect of acetylcysteine
administration; however, in the present study, none of the
patients receiving acetylcysteine showed hypotension during
hemodialysis, probably because of the slow continuous ad-
ministration during the hemodialysis session.
First, we evaluated the effect of acetylcysteine on plasma
homocysteine concentration. Under control conditions, the
plasma homocysteine concentration was reduced from
19.89.2 to 11.97.8 mol/L after a hemodialysis session.
In the presence of acetylcysteine, the plasma homocysteine
concentration was reduced from 20.18.5 to 2.21.2
mol/L after a hemodialysis session. The reduction of plasma
homocysteine concentration during a hemodialysis session
was significantly more pronounced in the presence of acetyl-
cysteine (Figure 2). Under control conditions, a hemodialysis
session reduced plasma homocysteine concentration to
5822% predialysis, whereas in the presence of acetylcys-
teine, a hemodialysis session reduced plasma homocysteine
concentration to 127% predialysis (P0.01 acetylcysteine
versus placebo control). We also analyzed the data in 15
patients showing kt/V values above 1.2. In these patients,
under control conditions, a hemodialysis session reduced
plasma homocysteine concentration to 5318% predialysis,
whereas in the presence of acetylcysteine, a hemodialysis
session reduced plasma homocysteine concentration to
117% predialysis (P0.01 acetylcysteine versus placebo
control).
There was a significant correlation between the ratio of
urea after and before hemodialysis and the ratio of homocys-
teine after and before hemodialysis (y0.14x26.8; r20.20;
P0.01), confirming that removal of homocysteine is related
to dialysis dose. However, the ratio of urea after and before
hemodialysis was not significantly different between the 2
groups (placebo control versus acetylcysteine).
The beneficial effect of acetylcysteine could be detected
even 2 days after its administration. At this time, the plasma
homocysteine concentration under control conditions was
13465% predialysis. In contrast, 2 days after administration
of acetylcysteine, the plasma homocysteine concentration
was 8836% predialysis.
Next, we investigated whether normalization of plasma
homocysteine concentration influenced hemodynamics in
patients with end-stage renal failure. The changes of heart
rate, systolic and diastolic blood pressure, and pulse pressure
are shown in Table 2. Under placebo control conditions, pulse
pressure did not significantly change during a hemodialysis
session (7720 versus 8024 mm Hg), whereas in the
presence of acetylcysteine, the pulse pressure was signifi-
cantly reduced from 8617 to 7622 mm Hg at the end of
the hemodialysis session (P0.05). As indicated in Figure 3,
the reduction of plasma homocysteine concentration from the
acetylcysteine group and the placebo group was significantly
correlated with a reduction of pulse pressure. A 10% decrease
in plasma homocysteine concentration was associated with a
decrease of pulse pressure by 2.5 mm Hg. Multivariate
TABLE 1. Clinical and Biochemical Characteristics of 20
Patients With End-Stage Renal Failure
Age, y 7011
Female 6 (30)
Body weight, kg 6614
Renal disease (%)
Diabetic nephropathy 6 (30)
Nephrosclerosis 3 (15)
Tubulointerstitial nephritis 1 (5)
Polycystic kidney disease 2 (10)
Other/unknown 8 (40)
Months on hemodialysis 2854
Hemodialysis adequacy, Kt/V 1.10.3
Leukocytes, 109/L 106
Hemoglobin, g/dL 92
Platelets, 109/L 282152
Serum creatinine, mol/L 541168
Blood urea nitrogen, mmol/L 176
Total protein, g/L 647
Serum calcium, mmol/L 2.30.2
Serum phosphate, mmol/L 1.30.5
Continuous data are shown as meanSD. Systolic and diastolic blood
pressure and heart rate were measured immediately before the hemodialysis
session.
Figure 2. Bar graph showing plasma homocysteine concentra-
tion in patients with end-stage renal failure before (open bars)
and after (black bars) a hemodialysis session under control con-
ditions and in the presence of acetylcysteine. In a crossover
design, each patient received acetylcysteine intravenously dur-
ing a hemodialysis session and placebo for control during
another hemodialysis session. Data are meanSD from n20
patients. *P0.01 for the comparison before versus after hemo-
dialysis. P0.01 for the comparison of acetylcysteine versus
control.
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analysis showed that these changes of pulse pressure were
only dependent on changes of plasma homocysteine concen-
tration (regression coefficient, 0.504; 95% CI, 0.238 to
0.771), whereas Kt/V, ultrafiltration volume, and changes of
hematocrit or serum protein concentration had no effect.
To evaluate the hemodynamic effects of increased homo-
cysteine removal during hemodialysis in the presence of
acetylcysteine, we investigated pulse waves during the hemo-
dialysis session. Figure 4 shows summary data for ab ratios
and ad ratios derived from analysis of the second derivative of
photoplethysmogram waveforms. The ab ratio decreased
during the hemodialysis session under control conditions,
whereas in the presence of acetylcysteine, the ab ratio
increased (P for trend 0.01). The ad ratio, mainly charac-
terizing peripheral arterial wave reflectance, decreased during
the hemodialysis session under control conditions, whereas in
the presence of acetylcysteine, the ad ratio increased (P for
trend 0.01).
To evaluate whether these changes of pulse waves in the
presence of acetylcysteine could reflect improvement in
endothelial function, we tested the endothelium-dependent
flow-mediated vasodilation during reactive hyperemia and
endothelium-independent vasodilation during nitroglycerine
administration on ab ratio and ad ratio in healthy subjects. As
shown in Figure 5, endothelium-dependent flow-mediated
vasodilation, but not endothelium-independent vasodilation,
significantly increased both ab ratio and ad ratio, respec-
tively. This means that an increase in ab ratio and ad ratio,
which was observed in patients with end-stage renal failure in
the presence of acetylcysteine, is in accordance with an
improvement of endothelial function.
Discussion
The present study shows that in the presence of acetylcys-
teine, plasma homocysteine concentration was markedly
lowered beyond the effects of hemodialysis alone. Addition-
ally, in the presence of the antioxidant acetylcysteine, im-
proved endothelial function could be observed.
Several attempts have been made to reduce elevated
plasma homocysteine concentration in patients with end-
TABLE 2. Hemodynamic Parameters in 20 Patients With
End-Stage Renal Failure Before and After a Hemodialysis
Session Under Control Conditions (Placebo) and in the
Presence of Acetylcysteine (ACC)
Characteristic/Treatment
Before
Hemodialysis
After
Hemodialysis P
Heart rate, bpm
Placebo 7311 8218 0.028
ACC 8022 8721 0.052
Systolic blood pressure, mm Hg
Placebo 14920 15028 0.948
ACC 15421 14827 0.500
Diastolic blood pressure, mm Hg
Placebo 7214 7014 0.291
ACC 6815 7219 0.188
Pulse pressure, mm Hg
Placebo 7720 8024 0.507
ACC 8617 7622 0.030
Data are meanSD.
Figure 3. Correlation between changes of plasma homocysteine
concentration and pulse pressure changes. Regression analysis
of changes of plasma homocysteine concentration and changes
of pulse pressure in patients with end-stage renal failure. The
ratio of plasma homocysteine concentration after and before a
hemodialysis session was plotted against the ratio of pulse
pressure after and before a hemodialysis session. Linear regres-
sion line and 95% CI are shown (r20.14, P0.019).
Figure 4. Summary data showing changes of photoplethysmo-
gram waveform characteristics in patients with end-stage renal
failure during a hemodialysis session. The ab ratios (top) and ad
ratios (bottom) were calculated from a second derivative of pho-
toplethysmogram waveform. Both ratios were measured at dif-
ferent points during a hemodialysis session under control condi-
tions (placebo) and in the presence of acetylcysteine and are
given as percent of initial control value obtained before hemodi-
alysis. Data are meanSD.
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stage renal failure. However, even high concentrations of
folic acid did not normalize elevated plasma homocysteine
concentration in these patients.10 The present study now
shows that the intravenous administration of acetylcysteine
during a hemodialysis session is able to completely normalize
plasma homocysteine concentration in patients with end-
stage renal failure.
The effects of oral acetylcysteine administration on plasma
homocysteine concentration have been reported previously.
Oral administration of acetylcysteine reduced plasma homo-
cysteine concentration in healthy women.20 A recent study
additionally showed that hemodialysis patients treated with
oral acetylcysteine for 4 weeks had a significant 19% reduc-
tion of plasma homocysteine concentration, whereas in the
placebo group, no significant reduction occurred. The differ-
ences between the acetylcysteine group and the placebo
group showed a P value of 0.07.21 The intravenous adminis-
tration of acetylcysteine was also shown to reduce plasma
homocysteine concentration in healthy subjects.13 In comple-
tion of these findings, the investigation presented here is the
first report on intravenous administration of acetylcysteine in
patients with end-stage renal failure. The increased reduction
of homocysteine after intravenous administration of acetyl-
cysteine that we found is presumably related to a quick
displacement of homocysteine from protein-binding sites,
allowing an increased proportion of homocysteine to be
available for plasma clearance by hemodialysis, considering
the small size of homocysteine. It has been suggested that the
intradialytic decline of plasma homocysteine concentration
resulted from the removal of unbound homocysteine, whereas
the sustained reduction of plasma homocysteine after hemo-
dialysis had been attributed to the elimination of uremic
toxins with inhibitory activity against enzymes involved in
the metabolism of homocysteine.22 However, additional ef-
fects of acetylcysteine on homocysteine metabolism may
contribute to its beneficial properties.
There is strong evidence that the reduction of elevated
plasma homocysteine concentration in patients with end-
stage renal failure is of clinical importance. First, a recent
study showed an association of quartiles of plasma homocys-
teine concentration with mortality in patients with end-stage
renal failure.23 Second, a prospective study showed that the
relative risk for cardiovascular events, including death, in-
creased 1% per micromolar increase in plasma homocysteine
concentration.5 The present study now shows that the reduc-
tion of plasma homocysteine concentration was convincingly
associated with improved endothelial function and improve-
ment, and hence reduction, of pulse pressure.
The finding of our study that a 10% decrease in plasma
homocysteine concentration in patients with end-stage renal
failure was associated with a decrease of pulse pressure by
2.5 mm Hg constitutes an important observation and is in
accordance with a recent study showing that acute hyperho-
mocysteinemia in healthy subjects increases pulse pressure.24
Moreover, elevated pulse pressure has been shown to be an
independent predictor of mortality in patients with end-stage
renal failure, a fact that underlines the importance of reducing
pulse pressure.25 Increased central arterial stiffness and alter-
ation of pulse wave reflections generated from peripheral
arteries contribute to the increase in pulse pressure observed
with age, hypertension, or end-stage renal failure. Analysis of
the second derivative of photoplethysmogram waveform has
repeatedly been used to evaluate peripheral arterial wave
reflectance.26 Using an analysis of pulse waves obtained from
fingertip photoplethysmography, Chowienczyk et al27
showed that endothelial-dependent vasodilation induced by
albuterol was attenuated with NG-monomethyl-L-arginine and
blunted in diabetic patients with endothelial dysfunction. We
used characteristic ratios derived from the second derivative
of photoplethysmogram waveforms to describe the hemody-
namic changes during a hemodialysis session. This approach
demonstrated an improvement in endothelial function in
patients with end-stage renal failure, because the same pattern
was observed during endothelium-dependent flow-mediated
vasodilation in healthy subjects. The fact that patients with
end-stage renal failure largely suffer from endothelial dys-
function underlines the importance of these findings.
Several mechanisms may be responsible for the improved
endothelial function under acetylcysteine treatment. First,
there are several lines of evidence that increased oxidative
stress is responsible for endothelial dysfunction in patients
with end-stage renal failure.7 Because it has been repeatedly
shown that acetylcysteine has antioxidative properties, it thus
may improve endothelial function. Second, homocysteine,
which itself is associated with oxidative stress, was shown to
induce programmed cell death in endothelial cells.28 Third,
homocysteine increases asymmetric dimethylarginine, an ure-
mic toxin, that impairs endothelium-dependent vasodila-
tion.29,30 In accordance with these results, regression analysis
Figure 5. Characteristics of endothelium-dependent and endo-
thelium-independent vasodilation using fingertip photoplethys-
mography. The ab ratios and ad ratios were calculated from a
second derivative of photoplethysmogram waveform in healthy
control subjects. The ab ratios and ad ratios (percent of initial
control value obtained under resting conditions) were measured
at endothelium-dependent flow-mediated vasodilation during
reactive hyperemia and at endothelium-independent vasodilation
during nitroglycerine administration. Data are meanSD.
*P0.05 and **P0.01 compared with control.
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showed that improvement of endothelium-dependent vasodi-
lation correlated closely with the reduction in free plasma
homocysteine concentration.31 Therefore, increased removal
of homocysteine should be a causative factor for the shown
improvement of endothelial function in the present study.
In conclusion, the intravenous administration of acetylcys-
teine normalizes plasma homocysteine concentration. This
was significantly associated with an improvement of pulse
pressure and endothelial function. Because the effects de-
scribed here are correlative, additional outcome studies with
a different study design may be warranted. However, these
effects may explain the published beneficial effects of ace-
tylcysteine on cardiovascular morbidity in patients with
end-stage renal failure, and, therefore, intravenous adminis-
tration of acetylcysteine during the hemodialysis session
might be a novel, promising approach to reduce arterioscle-
rotic risk in patients with end-stage renal failure.
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